Early Viral Effects of Entecavir and Adefovir Dipivoxil in Treatment of Chronic Hepatitis B

Objective:To evaluate the recent effect of entecavir(ETV) and adefovir dipivoxil(ADV) for the treatment of chronic hepatitis B.Methods:Patients of test group take ETV 0.5 mg per day while those of control group use ADV 10 mg per day.Liver function and quantitative HBV DNA were tested before and 4,12,24 weeks later.Results:There was no significant difference of HBV DNA level between two groups' baseline level (P0.05).HBVDNA decrease in ETV group were 2.60±0.85、3.22±1.24、3.06±1.29 log cp/mL at 4,12,24 weeks respectively after therapy and higher than those in ADV group(1.69±0.82、2.03±1.10、2.00±1.25) (P0.05);The rates of viral response in ETV and ADV group were 82% and 69% respectively;but ALT normality rate in two group were 64%.Meantime in entecavir group, there were 2 patients' ALT level significantly rose to values more than two times of baseline at 4 weeks, but their ALT and HBVDNA were recovered completely 8 weeks later.Conclusion: Entecavir showed stronger antivival effects for HBV than adefovir dipivoxil except for chemistry response.Cases with significantly increased ALT level after entecavir treatment might have relatively good prognosis.